Our novel platform employs field-grown tobacco plants as self-sustained, renewable energy-driven “bioreactors” that constitutively express recombinant proteins with innate proprietary purification and integrated immunogenic sugars removing mechanisms.
Unlike any of the currently available expression systems, our platform offers animal, human, or microbial origin free APIs for the production of biologics.
Clean rooms are not required in our upstream process and have a significantly smaller footprint in the downstream process.
Our process also completely eliminates the use of expensive bioreactors and media and the need for other sophisticated, limiting, and costly equipment.
Adalimumab (sold under the brand name Humira®)
is a blockbuster — $20 billion annual sales (fiercepharma.com) — biologic that is part of the tumor necrosis factor-alpha (TNF-α) blocker family of drugs.
Adalimumab is the first fully human therapeutic monoclonal antibody (mAb) approved for clinical use by the FDA.
Used to treat a number of inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and psoriasis.
The need for Humira is enormous, with more than
100 million patients worldwide suffering from these conditions.
The market is far from saturated. Due to its high price, even in developed countries, only 1 out of 1000 patients* in need can afford it.
We are not stopping here.
We plan to produce other drugs as anti-cancer drugs and novel biologics
using our plant based bioreactors.
Humira and all the biosimilar adalimumab currently produced in the Chinese Hamster Ovary (CHO) cell line have very limiting and expensive production methods
We have successfully produced adalimumab with our protein production platform technology. Our vision is to drastically reduce the end price by two orders of magnitude (to $1 a day), which will cause radical changes in the pharma market.